

Special Issue

Tuberculosis and Non-tuberculous Mycobacterial Infections: Control, Diagnosis and Antimicrobial Therapies

Message from the Guest Editor

It is estimated that approximately 1 billion people are currently infected with *Mycobacterium tuberculosis*, the causative agent of tuberculosis (TB). Moreover, the incidence of infections with non-tuberculous mycobacteria (NTM) is exponentially increasing, frequently surpassing new TB infections in developed countries. Collectively, TB and NTM infections represent a significant global healthcare crisis which is further exacerbated by the increased emergence of multidrug resistance and the lack of novel therapies. In this Special Issue of *Antibiotics*, we are seeking original research articles, short communications, reviews, case reports, and perspectives that cover but are not limited to the following topics:

- Control measures to combat TB and NTM infections;
- Diagnosis for the identification of TB and NTM infection;
- Novel antimicrobial therapies and new therapeutic drug targets;
- Mechanisms of antimicrobial resistance in TB and NTM species;
- New cellular and animal models to examine the efficacy of antimicrobial therapies against TB and NTM infections.

Guest Editor

Dr. Matt D. Johansen

Centre for Inflammation, Centenary Institute & University of Technology
Sydney, Missenden Rd, Camperdown, NSW 2050, Australia

Deadline for manuscript submissions

closed (31 January 2023)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/108657

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)